Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Medical Disability Clear all

Conditions: Mild Cognitive Impairment (MCI), Depression
Interventions: Escitalopram, Memantine, Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 60 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Intellectual Disability, Variable
Interventions: Pre-Dental Telehealth (PDT); Behavioral
Lead sponsor: Boston University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Upper Extremity Impairments, Cerebral Palsy (CP), ALS - Amyotrophic Lateral Sclerosis, Rett Syndrome
Interventions: One-week trial of Obi Medical device, which provides robotic assistance with feeding to persons with upper extremity impairments who are unable to self-feed in the traditional manner using utensils; Device
Lead sponsor: Desin LLC; Industry
Eligibility: 5 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Prader-Willi Syndrome
Interventions: Not listed
Lead sponsor: Foundation for Prader-Willi Research; Other
Eligibility: 5 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Walnut, California

Conditions: ADNP, Helsmoortel-Van Der Aa Syndrome, Autism Spectrum Disorder
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 2 Years and older
Enrollment: 30 participants
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Intellectual Disabilities, Congenital Anomaly, Rare Disorders
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 4 Weeks to 99 Years
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Depression
Interventions: Citalopram, Methylphenidate (MPH), Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 60 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Disability Physical
Interventions: Decision-making tool; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Peer-Support Intervention, Military-to-Civilian Transition, Medical Disability, Suicide Prevention, Pilot Randomized Controlled Trial
Interventions: Telephone- Based Peer Support + TAU; Behavioral
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: DDX3X, Mental Retardation, X-linked 102, Autism Spectrum Disorder
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 2 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: FOXP1, Mental Retardation With Language Impairment and With or Without Autistic Features, Autism Spectrum Disorder
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 2 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes (T2DM), Geriatric Syndromes, Disability Hearing, Disability Physical, Urinary Tract Infection(UTI), Delirium Confusional State
Interventions: Cinematic Virtual Reality Training, Traditional Didactic Lecture; Behavioral
Lead sponsor: Ohio University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency, Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan and Epilepsy), Alpha-Dystroglycanopathy (Dystroglycanopathy, Congenital With or Without Mental Retardation (Formerly MDC1C)), Alpha-Dystroglycanopathy (Fukuyama CMD), Alpha-Dystroglycanopathy (LGMDR09 FKRP Related (Formerly LGMD2I)), Alpha-Dystroglycanopathy (LGMDR11 POMT1 Related (Formerly LGMD2K)), Alpha-Dystroglycanopathy (LGMDR13 FKTN Related (Formerly LGMD2M)), Alpha-Dystroglycanopathy (LGMDR14 POMT2 Related (Formerly LGMD2N)), Alpha-Dystroglycanopathy (LGMDR15 POMGnT1 Related (Formerly LGMD2O)), Alpha-Dystroglycanopathy (LGMDR19 GMPPB Related (Formerly LGMD2T)), Alpha-Dystroglycanopathy (LGMDR20 ISPD Related (Formerly LGMD2U)), Alpha-Dystroglycanopathy (LGMDR24 POMGnT2 Related), Alpha-Dystroglycanopathy (Muscle Eye Brain Disease (MEB)), Alpha-Dystroglycanopathy (Walker Warburg Syndrome (WWS)), Choline Kinase B Receptor - CHKB, Collagen VI Related Disorders, Collagen XII Related Disorders, Congenital Muscular Dystrophy Not Otherwise Specified (Including Merosin Positive), Congenital Muscular Dystrophy With Cataracts and Intellectual Disability (MDCCAID), Congenital Muscular Dystrophy With Joint Hyperlaxity, Congenital Muscular Dystrophy With Rigid Spine Related to ACTA1, Emery-Dreifuss Muscular Dystrophy, GOLGA2-related Congenital Muscle Dystrophy With Brain Involvement, LMNA Related Disorders, Merosin Deficient CMD (Full or Partial), Nesprin Related MD (SYNE1), SELENON Related Disorders (Previously Known as SEPN1), SELENON Related Myopathy (Aka SEPN1), Telethonin CMD, Congenital Myasthenic Syndrome, Limb-Girdle Muscular Dystrophy, LGMDD01 - DNAJB6 (Formerly LGMD1D), LGMDD05 - Collagen VI Related Bethlem Myopathy (Dominant), LGMDR07 - Telethonin (TCAP) Related (Formerly LGMD2G), LGMDR08 - TRIM Related (Formerly LGMD2H), LGMDR09 - FKRP Related (Formerly LGMD2I), LGMDR10 - Titin (TTN) Related (Formerly LGMD2J), LGMDR11 - POMT1 Related (Formerly LGMD2K), LGMDR13 - Fukutin (FKTN) Related (Formerly LGMD2M), LGMDR14 - POMT2 Related (Formerly LGMD2N), LGMDR15 - POMGnT1 Related (Formerly LGMD2O), LGMDR16 - DAG1 Related Dystroglycanopathy (Formerly LGMD2P), LGMDR17 - Plectin (PLEC) Related (Formerly LGMD2Q), LGMDR18 - TRAPPC11 Related (Formerly LGMD2S), LGMDR19 - GMPPB Related (Formerly LGMD2T), LGMDR20 - ISPD Related (Formerly LGMD2U), LGMDR22 - Collagen VI Related Bethlem Myopathy (Recessive), LGMDR23 - LAMA2 Related, LGMDR24 - POMGnT2 Related
Interventions: Not listed
Lead sponsor: Cure CMD; Other
Eligibility: Not listed
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2029
U.S. locations: 1
States / cities: Lakewood, California

Conditions: Developmental Disabilities, Sleep Disorders, Polysomnography, Preparation for Medical Procedure, Child
Interventions: Educational Story; Other
Lead sponsor: Jennifer Accardo; Other
Eligibility: 4 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Back Pain
Interventions: Savella; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Type 2 Diabetes, Physical Disability
Interventions: High-Tech, Low-Tech, Attention Control; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Growth & Development, Child Development, Internship and Residency, Education, Medical, Developmental Disabilities
Interventions: performance feedback with an educational module; Procedure
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: Not listed
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Down Syndrome, Edwards Syndrome, Patau Syndrome, Klinefelter Syndrome, Turner Syndrome, DiGeorge Syndrome, Chromosome Deletion, Aneuploidy
Interventions: Blood sampling for Laboratory Developed Test (LDT) analysis; Other
Lead sponsor: Progenity, Inc.; Industry
Eligibility: 18 Years to 54 Years · Female only
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 8
States / cities: Scottsdale, Arizona • Eunice, Louisiana • Brooklyn, New York + 5 more

Conditions: Child, Only, Disabilities Multiple, Medication Interaction, Medication Compliance, Medication Administered in Error
Interventions: Pediatric Medication Therapy Management (pMTM); Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 2 Years to 18 Years
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Acute Low-back Pain, Chronic Low-back Pain, Pain, Intractable
Interventions: Duotherm VibraCool Back Device, TENS 8-channel unit; Device
Lead sponsor: MMJ Labs LLC; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Landover, Maryland • Fairfax, Virginia

Search by objective public record fields.

Brain Aging and Treatment Response in Geriatric Depression

A Pilot Project to Facilitate Dental Care and Reduce Barriers For Youth With Disabilities

Obi Medical Robot: Evaluating Effectiveness Related to Usability

Natural History Study of Serious Medical Events in PWS

ADNP Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing ADNP-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

Genome Medical Sequencing for Gene Discovery

Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression

Pilot Testing a New Pregnancy Decision Making Tool for Women With Physical Disabilities

Peer-Support Cognitive Behavioral Intervention for Military Life Transitions (Mil-iTransition)

DDX3X Syndrome -The Seaver Autism Center for Research and Treatment is Characterizing DDX3X-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

FOXP1 Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing FOXP1-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

Using Virtual Reality to Improve Medical Training

Congenital Muscle Disease Study of Patient and Family Reported Medical Information

Use of an Educational Story to Prepare Children With Developmental Disabilities for Sleep Study

Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran

Medical Nutrition Therapy and Diabetes Self-Management Education for People With Disabilities

Resident Surveillance of Pediatric Patient Developmental Status at the Two Month Preventive Care Visit

Expanded Noninvasive Genomic Medical Assessment: The Enigma Study

Pediatric Medication Therapy Management Trial

Impact of DuoTherm Compared to TENS on Pain and Disability With Acute and Chronic Low Back Pain